We featured in last nights' Channel 5's "Wonders of the Human Body". We were deeply saddened to learn of Dr. Michael Mosley’s passing and are honoured to be part of one of Dr Mosley's final TV projects. Catch up on the episode, aired yesterday at 8pm, which highlights the deliberate infection of volunteers to aid scientific research. Learn more about the series: https://lnkd.in/eeKjhSiT #Channel5 #HVO #ScientificResearch
hVIVO
Biotechnology Research
London, England 11,321 followers
The world leader in testing infectious and respiratory disease vaccines & therapeutics using human challenge trials.
About us
hVIVO plc (ticker: HVO) is a fast growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies. The Group's fast-growing services business includes a unique portfolio of 11 human challenge models, with a number of new models under development, to test a broad range of infectious and respiratory disease products. The Group has world class challenge agent manufacturing capabilities, specialist drug development and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The Group offers additional clinical field trial services such as patient recruitment and clinical trial site services. hVIVO runs challenge trials in London - its new state-of-the-art facilities in Canary Wharf opened in 2024 and is the world's largest commercial human challenge trial unit, with highly specialised on-site virology and immunology laboratories, and an outpatient unit. To recruit volunteers / patients for its studies, the Group leverages its unique clinical trial recruitment capability via its FluCamp volunteer screening facilities in London and Manchester.
- Website
-
http://www.hvivo.com
External link for hVIVO
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- London, England
- Type
- Public Company
- Founded
- 1989
- Specialties
- clinical trials, uk clinical trials, clinical research, challenge models, human challenge models, human volunteer research, respiratory disease research, medical research, asthma studies, copd, influenza, human models of disease, clinical research, challenge studies, human challenge trials, RSV, malaria, HRV, Respiratory syncytial virus, Human rhinoviruse, lab services, and covid 19
Locations
-
Primary
40 Bank Street
London, England E14 5NR, GB
Employees at hVIVO
Updates
-
Describing the world's largest human challenge trial facility in 3 words...or more! Check out what some of the members of management think about our new facility in #CanaryWharf. Here are some key insights to our facility: ✅ Custom designed 👉 Total useable space increased by 31% 🔬 Capability to run multiple human challenge studies concurrently 👩🔬 Increased breadth of challenge models to include CL3 designated pathogens 💪 Enhanced operational efficiencies #HVO #CHIM #ChallengeTrials #ScientificResearch #London #LifeSciences
-
A reminder that our CEO Yamin 'Mo' Khan Khan and CFO Stephen Pinkerton will be presenting our interim results for 6-months ended 30 June 2024 with Investor Meet Company. You can register to attend & submit questions here: https://lnkd.in/eastUNMs #Interims #Results #AIM #HVO
-
We featured in a UK Investor Magazine article: 📈 30.6% revenue growth on H1 2023 👩🔬 Record number of volunteer inoculations 👀 Cavendish analysts view ✅ Janus Henderson on why they added #HVO to the Henderson Smaller Companies Trust Read full article: https://lnkd.in/eTF4_ri6 #HVO #AIM #CHIM
-
Interesting BBC News article which explores the motivations behind volunteers participating in human challenge trials which involves being exposed to pathogens to advance scientific and medical research. 🔬 The crucial role volunteers play in accelerating vaccine & treatment development 🙌 Ethical considerations and importance of informed consent 👨🔬 Contributing to scientific progress 🦠 Why human challenge trials are vital for understanding diseases & improving public health Read the full article here: https://lnkd.in/gQmZygjx #HVO #ChallengeTrials #CHIM #ScientificResearch #Volunteers
Why some people are volunteering to be infected with diseases
bbc.com
-
Our Chief Scientific Officer Andrew Catchpole discusses Human Challenge Trials: 👨🔬 Being CSO at hVIVO ✅ Benefits of Human Challenge Trials 🎯 Recent trends in the industry 🔬 New state-of-the-art facility & delivering our results 💊 Accelerating drug development The full interview is also available on our #YouTube channel: https://lnkd.in/eteKGj4k #HVO #ScientificResearch #CHIM #ChallengeTrials
-
Controlled Human Infection Models (CHIM) are revolutionising the approach to vaccine development by offering a faster, more precise, and efficient approach to studying vaccine efficacy. 💉 🚀 There have been recent advancements in vaccine development, expedited by clinical trials conducted at hVIVO. ✨ Discover more by reading this blog: https://lnkd.in/g4vXwBn7 #HVO #CHIM #HumanChallenge #Vaccine #ClinicalTrials
-
Our Director of Clinical Operations Melanie Smyth MSc discusses the move to Canary Wharf: 👩🔬 Working at hVIVO 🏙️ How Canary Wharf benefit's clinical operations 💪 The move & impact on the team 🔬 Safety measures to ensure maximum care for volunteers Full also available on hVIVO's YouTube Channel: https://lnkd.in/eZUsYRpv #HVO #CanaryWharf #Clinical #CHIM
-
We will be heading to Vienna to attend the @ERS Congress, an annual event that brings together the world’s respiratory experts to showcase all the latest advances in respiratory medicine and science 🛫 Meet with our colleagues Egle Pavyde and Alexander Mann to discuss hVIVO’s support of field-based airway disease trials, as well as our world leading reputation for testing vaccine and drug efficacy in human challenge trials. Learn more about how our new 50 bed inpatient facility in Canary Wharf and X bed outpatient provision with supporting laboratories, all of which can help further advance respiratory medicine research 🔬 Connect 🤝with the team at the event or reach out directly to schedule a meeting! Learn more: https://lnkd.in/dWng7gC #ERS2024 #HVO #Conference #RespiratoryDisease
-
The hVIVO interim results for the six months to 30 June 2024 will be published on Tuesday 10 September. Our CEO Yamin 'Mo' Khan & CFO Stephen Pinkerton, will be presenting with Investor Meet Company at 6pm that evening. Register to attend: https://lnkd.in/e_aHRaQe #HVO #CompanyPresentation #Interims